전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
atazanavīrs
atazanavir
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs palielina
tenofovir-associated adverse
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
(atazanavīrs 300 mg
ritonavir 100 mg once daily)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
(atazanavīrs 300 mg/
(atazanavir 300 mg/ritonavir 100 mg
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs kopā ar kobicistatu
atazanavir with cobicistat
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs, vienlaicīga lietošana ar
atazanavir, simultaneous
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs, deva lietota 1 h pēc
atazanavir, dosed 1 hr after
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs ar kobicistatuf (n = 344)
atazanavir with cobicistatf (n = 344)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
aktīvās vielas ir atazanavīrs un kobicistats.
the active substances are atazanavir and cobicistat.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs ir vājš vai mērens cyp2c8 inhibitors.
atazanavir is a weak to moderate inhibitor of cyp2c8.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs tiek metabolizēts un eliminēts galvenokārt aknās.
atazanavir is metabolised and eliminated primarily by the liver.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
zāles, kuru darbību var ietekmēt atazanavīrs/kobicistats
medicinal products that may be affected by atazanavir/cobicistat
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
raltegravīrs 400 mg divreiz dienā (atazanavīrs 400 mg)
(atazanavir 400 mg)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
evotaz antiretrovirālo iedarbību nodrošina aktīvā viela atazanavīrs.
the antiretroviral effect of evotaz is due to the atazanavir component.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
pētījumi ar žurkām liecina, ka atazanavīrs izdalās pienā.
studies in rats have demonstrated that atazanavir is excreted in the milk.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
atazanavīrs ir azapeptīds, hiv-1 proteāzes inhibitors (pi).
atazanavir is an azapeptide hiv-1 protease inhibitor (pi).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
metadons, stabila balstdeva (atazanavīrs 400 mg vienreiz dienā)
methadone, stable maintenance dose (atazanavir 400 mg once daily)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
klīniskos pētījumos atazanavīrs ierosināja dislipidēmiju mazākā pakāpē nekā salīdzināmās zāles.
in clinical studies, atazanavir has been shown to induce dyslipidaemia to a lesser extent than comparators.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in vivo pētījumos pierādīts, ka atazanavīrs neinducē savu metabolismu un nepastiprina dažu, cyp3a4 metabolizētu zāļu biotransformāciju.
atazanavir has been shown in vivo not to induce its own metabolism, nor to increase the biotransformation of some medicinal products metabolised by cyp3a4.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
telaprevīrs 750 mg trīsreiz dienā (atazanavīrs/ritonavīrs 300/100 mg vienreiz dienā)
telaprevir 750 mg three times daily (atazanavir/ritonavir 300/100 mg once daily)
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: